FDA Approved: CAPRELSA — Original Application (Genzyme Corporation)

View source ↗

Summary

FDA approved Caprelsa (vandetanib) from Genzyme for the treatment of unresectable, metastatic medullary thyroid carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

ORIG AP for CAPRELSA (VANDETANIB)